Healthcare · Biotechnology
Price
$8.00
Market Cap
$516.2M
Employees
430
Beta
1.75
Avg Volume
840,469
CEO
Randy Teel
Business Description
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Business History
Price Overview
Last updated: Jun 27, 2026 11:22am (just now)$8.00
-0.03 (-0.37%)
Day Range
$7.83 – $8.26
52-Week Range
$6.06 – $14.51
50-Day MA
$9.02
200-Day MA
$10.67
Volume
2,264,748.00
Analyst Price Targets
Low
$10.00
Consensus
$14.75
High
$20.00
(36 analysts)
Share Structure
Outstanding
64,521,198.00
Float
55,945,686.00
Free Float
86.7%
High free float
— 86.7% of shares trade freely, ~13.3% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-6.25
Stock Price: $8.00
EPS (Diluted): -1.28
EPS (Diluted): -1.28
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.77
Stock Price: $8.00
Total Equity: $433.80M
Shares: 64,900,000
Total Equity: $433.80M
Shares: 64,900,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.02
Market Cap: $516.17M
Total Debt: $400,000
Cash: $142.90M
EBITDA: -$75.30M
Total Debt: $400,000
Cash: $142.90M
EBITDA: -$75.30M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$635.7M
Market Cap: $516.17M
Total Debt: $400,000
Cash: $142.90M
Total Debt: $400,000
Cash: $142.90M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
2.93
Stock Price: $8.00
Revenue: $262.60M
Shares: 64,900,000
Revenue: $262.60M
Shares: 64,900,000
EV/Sales (Total value vs revenue — works when P/E can't)
API2.42
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
98.0%
Gross Profit: $257.40M
Revenue: $262.60M
Revenue: $262.60M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-43.8%
Operating Income: -$114.90M
Revenue: $262.60M
Revenue: $262.60M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-30.8%
Net Income: -$80.80M
Revenue: $262.60M
Revenue: $262.60M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-44.4%
Net Income: -$80.80M
Total Equity: $433.80M
Total Equity: $433.80M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-46.8%
Operating Income: -$114.90M
Tax Rate: -0.4%
Equity: $433.80M
Total Debt: $400,000
Cash: $142.90M
Tax Rate: -0.4%
Equity: $433.80M
Total Debt: $400,000
Cash: $142.90M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
4.92
Current Assets: $700.70M
Current Liabilities: $142.50M
Current Liabilities: $142.50M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $400,000
Total Debt: $400,000
Total Equity: $433.80M
Long-Term Debt: $400,000
Total Debt: $400,000
Total Equity: $433.80M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$4.05
Revenue: $262.60M
Shares: 64,900,000
Shares: 64,900,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$6.68
Total Equity: $433.80M
Shares: 64,900,000
Shares: 64,900,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-4.25
Operating CF: -$273.80M
CapEx: -$1.90M
Shares: 64,900,000
CapEx: -$1.90M
Shares: 64,900,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $8.00
Stock Price: $8.00
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$80.80M
Net Income: -$80.80M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ARVN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:21pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $53.6M | $131.4M | $78.5M | $263.4M | $262.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $5.2M |
| Gross Profit | $53.6M | $131.4M | $78.5M | $263.4M | $257.4M |
| Operating Expenses | $242.0M | $394.6M | $480.0M | $513.6M | $372.3M |
| Operating Income | -$188.4M | -$263.2M | -$401.5M | -$250.2M | -$114.9M |
| Net Income | -$191.0M | -$282.5M | -$367.3M | -$198.9M | -$80.8M |
| EBITDA | -$184.9M | -$253.4M | -$359.7M | -$191.7M | -$75.3M |
| EPS | $-3.82 | $-5.31 | $-6.62 | $-2.77 | $-1.28 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:21pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $108.3M | $81.3M | $311.7M | $100.5M | $142.9M |
| Total Current Assets | $1.6B | $1.2B | $1.3B | $1.1B | $700.7M |
| Total Assets | $1.6B | $1.3B | $1.3B | $1.1B | $717.9M |
| Current Liabilities | $261.7M | $295.1M | $257.1M | $229.8M | $142.5M |
| Long-Term Debt | $1.0M | $1.0M | $800,000 | $600,000 | $400,000 |
| Total Liabilities | $799.9M | $703.9M | $644.6M | $529.7M | $284.1M |
| Total Equity | $781.7M | $564.9M | $660.0M | $561.7M | $433.8M |
| Retained Earnings | -$682.9M | -$965.4M | -$1.3B | -$1.5B | -$1.6B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:21pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $559.4M | -$273.5M | -$347.8M | -$259.3M | -$273.8M |
| Capital Expenditure | -$4.7M | -$6.8M | -$2.9M | -$1.8M | -$1.9M |
| Free Cash Flow | $554.7M | -$280.3M | -$350.7M | -$261.1M | -$275.7M |
| Acquisitions (net) | $0 | $400,000 | $0 | $100,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$91.9M |
| Net Change in Cash | -$475.6M | -$26.0M | $230.4M | -$216.7M | $42.4M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:39am (1h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$69.7M $30.4M – $143.0M
|
$68.7M $26.0M – $137.4M
|
$113.1M $42.8M – $226.2M
|
$176.6M $66.8M – $353.3M
|
| EBITDA |
-$56.0M -$114.9M – -$24.4M
|
-$55.2M -$110.4M – -$20.9M
|
-$90.8M -$181.6M – -$34.3M
|
-$141.8M -$283.7M – -$53.6M
|
| Net Income |
-$253.9M -$325.2M – -$152.2M
|
-$250.2M -$267.7M – -$100.9M
|
-$145.3M -$334.2M – -$27.8M
|
-$96.3M -$221.5M – -$18.4M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:21pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +145.1% | -40.3% | +235.5% | -0.3% |
| Gross Profit Growth | +145.1% | -40.3% | +235.5% | -2.3% |
| Operating Income Growth | -39.7% | -52.5% | +37.7% | +54.1% |
| Net Income Growth | -47.9% | -30.0% | +45.8% | +59.4% |
| EBITDA Growth | -37.0% | -41.9% | +46.7% | +60.7% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:39am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Smaldone Alsup Laurie | A-Award | 15,527.00 | $0.00 | $0 |
| 2026-06-24 | Smaldone Alsup Laurie | A-Award | 22,714.00 | $8.05 | $182,848 |
| 2026-06-24 | Norwalk Leslie V | A-Award | 15,527.00 | $0.00 | $0 |
| 2026-06-24 | Norwalk Leslie V | A-Award | 22,714.00 | $8.05 | $182,848 |
| 2026-06-24 | Morrison Briggs | A-Award | 15,527.00 | $0.00 | $0 |
| 2026-06-24 | Morrison Briggs | A-Award | 22,714.00 | $8.05 | $182,848 |
| 2026-06-24 | Kennedy Edward Moore Jr. | A-Award | 15,527.00 | $0.00 | $0 |
| 2026-06-24 | Kennedy Edward Moore Jr. | A-Award | 22,714.00 | $8.05 | $182,848 |
| 2026-06-24 | Cunningham Everett | A-Award | 15,527.00 | $0.00 | $0 |
| 2026-06-24 | Cunningham Everett | A-Award | 22,714.00 | $8.05 | $182,848 |
| 2026-06-24 | Bain Linda | A-Award | 15,527.00 | $0.00 | $0 |
| 2026-06-24 | Bain Linda | A-Award | 22,714.00 | $8.05 | $182,848 |
| 2026-06-24 | Saik Andrew | S-Sale | 5,696.00 | $8.16 | $46,474 |
| 2026-06-17 | Cacace Angela M | S-Sale | 2,576.00 | $7.60 | $19,565 |
| 2026-05-21 | Teel Randy | S-Sale | 2,209.00 | $9.04 | $19,962 |
| 2026-05-11 | Saik Andrew | S-Sale | 11,139.00 | $9.94 | $110,693 |
| 2026-05-11 | Loomis David K | S-Sale | 1,919.00 | $9.94 | $19,070 |
| 2026-05-11 | Cacace Angela M | S-Sale | 9,657.00 | $9.94 | $95,965 |
| 2026-05-11 | Berkowitz Noah | S-Sale | 11,108.00 | $9.94 | $110,385 |
| 2026-05-11 | Teel Randy | S-Sale | 9,657.00 | $9.94 | $95,965 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ARVN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ARVN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30